Blood Spot and Urine Metabolomic Screening Applied to Rare Diseases
Recruiting now · Not applicable
Conditions studied: Inborn Errors of Metabolism, Rare Diseases
In brief
The primary goal of this study is to establish a biobank of dried blood spots and urines from a large control cohort and collect several cohorts as large as possible of patients affected or suspected of being affected by rare diseases (mainly hereditary metabolic diseases) or by autism spectrum disorders. A metabolomic database using a high-resolution mass spectrometer (i.e. the "Device") will be generated and specific biomarkers for the diseases will be confirmed or uncovered. The ultimate goal is to facilitate and improve the diagnosis and screening of the patients affected by these disorders, but also to improve the knowledge about the biochemical mechanisms involved over the course of the selected pathologies. High-resolution mass spectrometry allows the measurement of thousands of metabolites in a single analysis. The current biochemical tests used for the diagnosis of hereditary metabolic diseases are only using a combination of maximum a few dozens of biomarkers in one analysis. Objectives Unravel new biomarkers for diagnosis (+/- explore the altered pathways…) Uncover and/or validate newborn screening biomarkers through retrospective analysis of preserved newborn DBS from confirmed patients (useful for first or second tier biochemical NBS testing!) Validation of LC-MS qTOF for metabolomics screening as first line diagnostic test (thousands of metabolites) using diagnostic algorithms (modified z-scores) \& continuous optimization by adding new cases and new controls in the database Generation of a biobank of urines and DBS from rare diseases (IEMs) \& from a large reference population useful for other research applications
Key facts
- Study ID
- NCT06360913
- Run by
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
- People needed
- 2286
- Starts
- 2024-01-03
- Expected to finish
- 2028-01-01
- Last updated by the study team
- 2024-04-12
Who can join
Age: 0 and older, up to 99. Sex: any. Healthy volunteers: accepted.
You may qualify if…
- Subjects from newborn to elderly, presumably not affected by a rare disease (Group 1) (Newborns: only residual DBS from newborn screening from full-term newborns and with a negative official newborn screening test, de-identified samples not requiring an ICF, no urine sample for this category), OR
- Patients from newborn to elderly, affected by a genetic metabolic disease (genetic confirmation is required) or another confirmed rare disease for which a metabolic derangement is suspected (Group 2), OR
- Patients from newborn to elderly, affected by autism spectrum disorders and evaluated according to the DSMV classification (Group 2), OR
- Patients suspected of being affected by a genetic metabolic disease or another rare disease with potential metabolic derangement (i.e. for which genetic and/or biochemical test(s) are non-conclusive or in progress) (Group 3)
You may not qualify if…
- Subjects or patients for which the data required for analysis and assignment in the correct subgroup are lacking
- No informed consent signed
Where it is running
- Cliniques universitaires Saint Luc — Brussels, Belgium (enrolling)
- Hôpital Universitaire des enfants Reine Fabiola (HUDERF-ULB) — Brussels, Belgium
- Institut de Pathologie et de Génétique (IPG) — Charleroi, Belgium
- CHU Liege — Liège, Belgium
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.